Wasan Kishor M, Brocks Dion R, Lee Stephen D, Sachs-Barrable Kristina, Thornton Sheila J
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada V6T 1Z3.
Nat Rev Drug Discov. 2008 Jan;7(1):84-99. doi: 10.1038/nrd2353.
In contrast to many traditional pharmaceutical agents that exhibit a high degree of aqueous solubility, new drug candidates are frequently highly lipophilic compounds. The aqueous environment of the blood provides a thermodynamically unfavourable environment for the disposition of such hydrophobic drugs. However, this limitation can be overcome by association with circulating lipoproteins. Elucidation of the mechanisms that dictate drug-lipoprotein association and blood-to-tissue partitioning of lipoprotein encapsulated drugs might yield valuable insight into the factors governing the pharmacological activity and potential toxicity of these compounds. This Review discusses the impact of hydrophobic drug-lipoprotein interactions on pharmacokinetics, drug metabolism, tissue distribution and biological activity of various hydrophobic compounds, and outlines how best to use this information in drug discovery and development programmes.
与许多具有高度水溶性的传统药物不同,新的候选药物常常是高亲脂性化合物。血液的水性环境为这类疏水性药物的处置提供了热力学上不利的环境。然而,通过与循环脂蛋白结合可以克服这一限制。阐明决定药物与脂蛋白结合以及脂蛋白包裹药物的血-组织分配的机制,可能会为控制这些化合物药理活性和潜在毒性的因素提供有价值的见解。本综述讨论了疏水性药物-脂蛋白相互作用对各种疏水性化合物的药代动力学、药物代谢、组织分布和生物活性的影响,并概述了如何在药物发现和开发计划中最好地利用这些信息。